Equity Investment Corp Reduces Position in GSK plc (NYSE:GSK)

Equity Investment Corp decreased its position in shares of GSK plc (NYSE:GSK - Free Report) by 1.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,243,259 shares of the pharmaceutical company's stock after selling 34,103 shares during the period. GSK comprises approximately 3.4% of Equity Investment Corp's holdings, making the stock its 5th biggest holding. Equity Investment Corp owned about 0.16% of GSK worth $120,195,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its holdings in GSK by 2,816.7% during the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company's stock worth $26,000 after acquiring an additional 676 shares in the last quarter. Larson Financial Group LLC grew its holdings in GSK by 271.8% during the 3rd quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company's stock worth $32,000 after acquiring an additional 647 shares in the last quarter. BKM Wealth Management LLC acquired a new position in GSK during the 4th quarter worth $32,000. Jones Financial Companies Lllp grew its holdings in GSK by 62.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company's stock worth $48,000 after acquiring an additional 509 shares in the last quarter. Finally, Princeton Global Asset Management LLC grew its holdings in GSK by 54.3% during the 4th quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company's stock worth $56,000 after acquiring an additional 533 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

Analyst Ratings Changes

GSK has been the subject of several research reports. Citigroup raised shares of GSK from a "neutral" rating to a "buy" rating in a report on Tuesday, February 13th. Morgan Stanley started coverage on shares of GSK in a research report on Tuesday, January 23rd. They issued an "equal weight" rating on the stock. Finally, Guggenheim upgraded shares of GSK from a "neutral" rating to a "buy" rating in a research report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy".

GSK Trading Up 0.2 %

Shares of GSK stock traded up $0.10 during trading on Friday, hitting $44.98. The stock had a trading volume of 1,882,986 shares, compared to its average volume of 3,478,259. The stock has a 50 day simple moving average of $42.32 and a 200 day simple moving average of $39.77. The company has a market capitalization of $93.22 billion, a PE ratio of 16.30, a P/E/G ratio of 1.93 and a beta of 0.65. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.15. GSK plc has a 1 year low of $33.33 and a 1 year high of $45.92.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be given a $0.3762 dividend. This is an increase from GSK's previous quarterly dividend of $0.36. This represents a $1.50 annualized dividend and a dividend yield of 3.35%. The ex-dividend date of this dividend is Thursday, May 16th. GSK's dividend payout ratio (DPR) is 53.26%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.